From: Buehler, Gary J Sent: Monday, August 11, 2003 6:47 AM To: Dockets, FDA Subject: FW: Generic ribavirin -----Original Message----- From: Harank, Michael ACMC [mailto:mharank@acmedctr.org] Sent: Thursday, August 07, 2003 3:51 PM To: 'buehler@cder.fda.gov' Subject: Generic ribavirin buehler@cder.fda.gov Dear Director Buehler and Dockets Management staff, I am writing to strongly urge FDA to immediately approve generic ribavirin capsules for use in the treatment of hepatitis C and to oppose the recently submitted "Citizen Petition" by the brand manufacture of this drug simply designed to delay that approval. The petition is yet another tactic by brand drug makers to misuse the FDA in a desperate effort to deny people with hepatitis C legal and timely access to competitive, safe, effective, lower cost equivalent treatments. Please approve generic ribavirin applications as soon as possible! Sincerely, Michael Harank RN Director HCV/HIV Project. Alameda County Medical Center, Oakland, California DISCLAIMER: This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.